Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.

Saved in:
Bibliographic Details
Title: Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.
Authors: Shah V; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany., Giotopoulos G; Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Osaki H; Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Meyerhöfer M; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany., Meduri E; Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Gallego-Crespo A; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany., Behrendt MA; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany., Saura-Pañella M; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany., Tarkar A; GlaxoSmithKline Research and Development, Collegeville, PA., Schubert B; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany., Yun H; Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Department of Medicine V, Hematology, Oncology, and Rheumatology, University of Heidelberg, Heidelberg, Germany., Horton SJ; Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Agrawal-Singh S; Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Haehnel PS; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany., Basheer F; Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Lugo D; Adaptive Immunity and Immuno-epigenetics Research Unit, GlaxoSmithKline Research and Development, Stevenage, United Kingdom., Eleftheriadou I; GlaxoSmithKline Research and Development, Collegeville, PA., Barbash O; GlaxoSmithKline Research and Development, Collegeville, PA., Dhar A; GlaxoSmithKline Research and Development, Collegeville, PA., Kühn MWM; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany.; Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany., Guezguez B; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany.; Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany., Theobald M; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany.; Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany., Kindler T; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany.; Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany., Gallipoli P; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Yeh P; Monash Haematology, Monash Health and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia., Dawson MA; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia., Prinjha RK; Adaptive Immunity and Immuno-epigenetics Research Unit, GlaxoSmithKline Research and Development, Stevenage, United Kingdom., Huntly BJP; Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Sasca D; Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; German Cancer Consortium, Mainz, Germany.; Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany.; Institute for Quantitative and Computational Biosciences, Johannes Gutenberg University, Mainz, Germany.
Source: Blood [Blood] 2025 Feb 13; Vol. 145 (7), pp. 748-764.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2022019306